Knight Therapeutics Inc. has announced an expansion of its partnership with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte. This amended agreement grants Knight exclusive rights to distribute two innovative biologic products, retifanlimab and axatilimab, in Latin America. Under the partnership, Incyte will handle the development, manufacture, and supply of these medicines, while Knight will focus on obtaining regulatory approvals and distribution in the region. This collaboration builds upon their existing agreement for other treatments, reinforcing Knight's commitment to enhancing its oncology and hematology portfolio in Latin America.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.